alosetron has been researched along with eluxadoline in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lembo, AJ; Nee, J; Zakari, M | 1 |
| Cash, BD; Earnest, DL; Lacy, BE; Rao, T | 1 |
| Lacy, BE | 1 |
| Morgan, B | 1 |
| Lacy, BE; Moreau, JC | 1 |
| Talley, NJ | 1 |
| Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R | 1 |
| Brenner, DM; Sayuk, GS | 1 |
5 review(s) available for alosetron and eluxadoline
| Article | Year |
|---|---|
Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Phenylalanine; Receptors, Opioid; Rifamycins; Rifaximin | 2015 |
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Topics: Abdominal Pain; Anti-Bacterial Agents; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Narcotic Antagonists; Phenylalanine; Receptors, Opioid; Rifamycins; Rifaximin; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Topics: Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Loperamide; Pancreatitis; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2016 |
Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
Topics: Carbolines; Diarrhea; Disease Management; Humans; Imidazoles; Irritable Bowel Syndrome; Parasympatholytics; Phenylalanine; Rifamycins; Rifaximin; United States | 2016 |
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Topics: Adult; Carbolines; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Syndrome; Phenylalanine; Quality of Life; Rifaximin; United States; United States Food and Drug Administration | 2020 |
3 other study(ies) available for alosetron and eluxadoline
| Article | Year |
|---|---|
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain | 2016 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Constipation; Diarrhea; Disease Management; Female; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Imidazoles; Irritable Bowel Syndrome; Laxatives; Loperamide; Peptides; Phenylalanine; Probiotics; Rifamycins; Rifaximin; Selective Serotonin Reuptake Inhibitors | 2016 |
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Aged; Carbolines; Diarrhea; Female; Health Resources; Humans; Imidazoles; Irritable Bowel Syndrome; Middle Aged; Phenylalanine; Quality of Life; Rifaximin | 2019 |